Download PDF
Pharmacopsychiatry 2002; 35(1): 6-11
DOI: 10.1055/s-2002-19831
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Effects of Anticholinergic Drug Withdrawal
on Memory, Regional Cerebral Blood Flow and Extrapyramidal Side Effects in Schizophrenic Patients

K.  Mori1, 2 , H.  Yamashita2 , M.  Nagao1 , J.  Horiguchi3 , S.  Yamawaki2
  • 1Nagao Mental Hospital
  • 2Department of Psychiatry and Neurosciences, Hiroshima University School of Medicine
  • 3Department of Psychiatry, Shimane Medical University School of Medicine, Japan
Further Information

Publication History

20. 7. 2000 · Revised 15. 1. 2001

10. 3. 2001

Publication Date:
30 January 2002 (online)

Also available at
    Permissions and Reprints

It has been suggested that anticholinergic drugs impair immediate memory and working memory in patients with schizophrenia. Opinions remain divided as to the influence of anticholinergic drug withdrawal on the psychopathology and extrapyramidal side effects (EPS) in these patients. In our previous study, regional cerebral blood flow (rCBF) was reduced in all regions of patients taking anticholinergic drugs. Anticholinergic drugs were withdrawn in 21 schizophrenic inpatients. Immediate and verbal working memory, rCBF, psychopathology, and EPS were investigated before and after anticholinergic withdrawal. There was improvement in immediate memory, verbal working memory, and psychopathology, as well as an increase in rCBF after withdrawal from anticholinergic drugs. EPS showed no significant changes. Factors that may predict the improvement of immediate memory after withdrawal of anticholinergic drugs are more severe baseline psychopathology and use of a higher anticholinergic drug dose at baseline. Improvement of working memory may be predicted by a higher baseline rCBF in the left anterior cerebral artery region. Withdrawal from anticholinergics should be considered in schizophrenic patients, and it is important to taper these drugs over at least four weeks.

References

  • 1 American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press 4th ed. 1994
    Google Scholar
  • 2 Baker L A, Cheng L Y, Amara I B. The withdrawal of benztropine mesylate in chronic schizophrenic patients.  Br J Psychiatry. 1983;  143 584-590
    PubMedGoogle Scholar
  • 3 Bech P. Rating Scales for Psychopathology. Health Status and Quality of Life. Springer-Verg, Berlin 1993: 1-43
    Google Scholar
  • 4 Bezchlibnyk-Butler K Z, Remington G J. Anti-Parkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.  Can J Psychiatry. 1994;  39 74-84
    PubMedGoogle Scholar
  • 5 Borison R L. The role of cognition in the risk - benefit and safety analysis of antipsychotic medication.  Acta Psychiatr Scand Suppl. 1996;  389 5-11
    PubMedGoogle Scholar
  • 6 Caine E D, Weingartner H, Ludlow C L, Cudahy E A, Wehry S. Qualitative analysis of scopolamine-induced amnesia.  Psychopharmacology (Berl). 1981;  74 74-80
    CrossrefPubMedGoogle Scholar
  • 7 Calev 1987 A, Korin Y, Kugelmass S, Lerer B. Performance of chronic schizophrenics on matched word and design recall tasks.  Biol Psychiatry. 1987;  22 699-709
    CrossrefPubMedGoogle Scholar
  • 8 Calev A. Recall and recognition in chronic nondemented schizophrenics: use of matched tasks.  J Abnorm Psychol. 1984a ;  93 172-177
    CrossrefPubMedGoogle Scholar
  • 9 Calev A. Recall and recognition in mildly disturbed schizophrenics: the use of matched tasks.  Psychol Med. 1984b ;  14 425-429
    PubMedGoogle Scholar
  • 10 Caroli F, Littre-Poirier M F, Ginestet D, Deniker P. Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics.  Encephale. 1975;  1 69-74
    PubMedGoogle Scholar
  • 11 de Leon J, Canuso C, White A O, Simpson G M. A pilot effort to determine benztropine equivalents of anticholinergic medications.  Hosp Community Psychiatry. 1994;  45 606-607
    PubMedGoogle Scholar
  • 12 de Oliveira 1 R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E. et al . Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.  J Clin Pharm Ther. 1996;  21 349-358
    CrossrefPubMedGoogle Scholar
  • 13 Donlon P T, Stenson R L. Neuroleptic induced extrapyramidal symptoms.  Dis Nerv Syst. 1976;  37 629-635
    PubMedGoogle Scholar
  • 14 Double D B. Unblinding in Trials of the Withdrawal of Anticholinergic Agents in Patients Maintained on Neuroleptics.  J NERV MENT DIS. 1995;  183 599-602
    PubMedGoogle Scholar
  • 15 Double D B, Warren G C, Evans M, Rowlands R P. Efficacy of maintenance use of anticholinergic agents.  Acta Psychiatr Scand. 1993;  88 381-384
    CrossrefPubMedGoogle Scholar
  • 16 Drachman D A. Memory and cognitive function in man: does the cholinergic system have a specific role?.  Neurology. 1977;  27 783-790
    PubMedGoogle Scholar
  • 17 Drachman D A, Leavitt J. Human memory and the cholinergic system; A relationship to aging?.  Arch Neurol. 1974;  30 113-121
    CrossrefPubMedGoogle Scholar
  • 18 Fennig S, Levine Y, Naisberg S, Elizur A. The effect of trihexphenidyl (Artane) on memory in schizophrenic patients.  Prog Neuropsychopharmacol Biol Psychiatry. 1987;  11 71-78
    CrossrefPubMedGoogle Scholar
  • 19 Fletcher P C, Shallice T, Dolan R J. The functional roles of prefrontal cortex in episodic memory. I. Encoding.  Brain. 1998;  121 1239-1248
    CrossrefPubMedGoogle Scholar
  • 20 Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.  Eur Neuropsychopharmacol. 1996;  6 13-20
    PubMedGoogle Scholar
  • 21 Gardos G, Cole J O, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs.  Am J Psychiatry. 1978;  135 1321-1324
    PubMedGoogle Scholar
  • 22 Green M F, Marshall BD J r, Wirshing W C, Ames D, Marder S R, McGurk S. et al . Does risperidone improve verbal working memory in treatment-resistant schizophrenia?.  Am J Psychiatry. 1997;  154 99-804
    PubMedGoogle Scholar
  • 23 Guy W. Early Clinical Drug Evaluation (ECDEU) assessment manual for psychopharmacology. Nat Inst Ment Health, Rockville 1976
    Google Scholar
  • 24 Hitri A, Craft R B, Fallon J, Sethi R, Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients.  Psychopharmacol Bull. 1987;  23 33-37
    PubMedGoogle Scholar
  • 25 Jellinek T, Gardos G, Cole J O. Adverse effects of antiparkinson drug withdrawal.  Am J Psychiatry. 1981;  138 1567-1571
    PubMedGoogle Scholar
  • 26 Johnson D A, Wright N F. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years.  Br J Psychiatry. 1990;  156 827-834
    PubMedGoogle Scholar
  • 27 Kane J M. Schizophrenia.  N Engl J Med. 1996;  334 34-41
    CrossrefPubMedGoogle Scholar
  • 28 Katz I R, Greenberg W M, Barr G A, Garbarino C, Buckley P, Smith D. Screening for cognitive toxicity of anticholinergic drugs.  J Clin Psychiatry. 1985;  46 323-326
    PubMedGoogle Scholar
  • 29 Lavin M R, Rifkin A. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects.  J Clin Pharmacol. 1991;  31 763-768
    PubMedGoogle Scholar
  • 30 McClelland H A, Blessed G, Bhate S, Ali N, Clarke P A. The abrupt withdrawal of anti-Parkinsonian drugs in schizophrenic patients.  Br J Psychiatry. 1974;  124 151-159
    PubMedGoogle Scholar
  • 31 McEvoy J P, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs.  Compr Psychiatry. 1989;  30 135-138
    CrossrefPubMedGoogle Scholar
  • 32 Mori K, Teramoto K, Nagao M, Horiguchi J, Yamawaki S. Regional cerebral blood flow in schizophrenia using stable xenon-enhanced computed tomography.  Neuropsychobiology. 1999;  39 117-124
    PubMedGoogle Scholar
  • 33 Nambu K, Suzuki R, Hirakawa K. Cerebral Blood Flow: Measurement with xenon-enhanced dynamic helical CT.  Radiography. 1995;  195 53-57
    PubMedGoogle Scholar
  • 34 Oltmanns T F, Neale J M. Schizophrenic performance when distractors are present. Attentional deficit or diggeneretial task difficulty?.  J Abnormal Psychology. 1975;  84 205-209
    PubMedGoogle Scholar
  • 35 Overall J E, Gorham D R. Brief Psychiatric Rating Scale.  Psychol Reps. 1962;  10 799-812
    CrossrefPubMedGoogle Scholar
  • 36 Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia.  Am J Psychiatry. 1986;  143 230-232
    PubMedGoogle Scholar
  • 37 Potamianos G, Kellett J M. Anti-cholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients.  Br J Psychiatry. 1982;  140 470-472
    PubMedGoogle Scholar
  • 38 Safer D J, Alien R P. The central effects of scopolamine in man.  Biol Psychiatry. 1971;  3 347-355
    PubMedGoogle Scholar
  • 39 Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study.  Br J Psychiatry. 1995;  166 241-243
    PubMedGoogle Scholar
  • 40 Simpson G M, Angus J WS. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand. 1970;  212 11-19
    PubMedGoogle Scholar
  • 41 Singh M M, Kay S R, OpIer L A. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping.  Psychol Med. 1987;  17 39-48
    PubMedGoogle Scholar
  • 42 Sitaram N, Weingartner H, Gillin J C. Human serial learning: enhancement with arecholine and choline impairment with scopolamine.  Science. 1978;  201 274-276
    PubMedGoogle Scholar
  • 43 Spohn H E, Strauss M E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.  J Abnorm Psychol. 1989;  98 367-380
    CrossrefPubMedGoogle Scholar
  • 44 Stevens A A, Goldman-Rakic P S, Gore J C, Fulbright R K, Wexler B E. Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging.  Arch Gen Psychiatry. 1998;  55 1097-1103
    PubMedGoogle Scholar
  • 45 Sweeney J A, Keilp J G, Haas G L, Hill J, Weiden P J. Relationships between medication treatments and neuropsychological test performance in schizophrenia.  Psychiatry Res. 1991;  37 297-308
    CrossrefPubMedGoogle Scholar
  • 46 Tamlyn D, McKenna P J, Mortimer A M, Lund C E, Hammond S, Baddeley A D. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character.  Psychol Med. 1992;  22 101-115
    PubMedGoogle Scholar
  • 47 Tran P V, Dellva M A, Tollefson G D, Beasley CM J r, Potvin J H, Kiesler G M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.  J Clin Psychiatry. 1997;  58 205-211
    PubMedGoogle Scholar
  • 48 Tune L E, Strauss M E, Lew M F, Breitlinger E, Coyle J T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.  Am J Psychiatry. 1982;  139 1460-1462
    PubMedGoogle Scholar
  • 49 Van der Linden M, Collette F, Salmon E, Delfiore G, Degueldre C, Luxen A. et al . The neural correlates of updating information in verbal working memory.  Memory. 1999;  7 549-560
    CrossrefPubMedGoogle Scholar
  • 50 Yamashita T, Nagatsugu Y, Ishihara H, Shiroyama Y, Wakuta Y, Kashiwagi S. Comparison of Xe-CT/CBF and quantitative ECD-SPECT.  Acta Neurol Scand Suppl. 1996;  166 6-9
    PubMedGoogle Scholar
  • 51 Yonas H, Pindzola R P, Johnson D W. Xenon/computed tomography cerebral blood flow and its use in clinical.  Neurosurg Clin N Am. 1996;  7 605-616
    PubMedGoogle Scholar

MD, PhD Shigeto Yamawaki

Department of Psychiatry and Neurosciences
Hiroshima University School of Medicine

1-2-3 Kasumi, Minami-ku

Hiroshima 734-8551

Japan

Phone: ++81 822575207

Fax: ++81 822575209

Email: yamawaki@hiroshima-u.ac.jp